alxn2080
Nucleic acidexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 12, 2022 (NCT05428696)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Complement C3ANTISENSE INHIBITOR
C3 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06173596 | Phase 1 | Dec 21, 2023 | Alexion |
| NCT06160414 | Phase 1 | Dec 13, 2023 | Alexion |
| NCT05428696 | Phase 1 | Sep 12, 2022 | Alexion, Celerion |
Showing 3 of 3 trials
Page 1 / 1